Hormone therapy is often used to prevent night sweats. But finding the right dose of estrogen can be tricky, with some women needing more estrogen than others to get relief. A new Mayo Clinic study published in Menopause: The Journal of the North American Menopause Society found that genetic differences appear to play a role in the effectiveness of hormonal treatment for menopausal women.
This week’s Research Roundup highlights the association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer.
According to Mayo Clinic research published in JAMA, six genes contain mutations that may be passed down in families, substantially increasing a person’s risk for pancreatic cancer.
Just as money in the bank boosts your financial well-being, biobanks have the power to impact your health. Think of biobank samples as assets that researchers can draw upon to improve disease treatments.
This week’s Research Roundup features highly discriminant methylated DNA markers for the non-endoscopic detection of Barrett’s esophagus.
Mayo Clinic laboratory workers have a new tool to perform high tech genetic sleuthing for the source of stubborn, sometimes life-threatening bacteria.
This week’s Research Roundup highlights the detection of gastric cancer with novel methylated DNA markers: discovery, tissue validation, and pilot testing in plasma.
Since ancient times, physicians have analyzed patient specimens to diagnose illness. Now, our samples can do far more than diagnose. They can help researchers find treatments for the unmet needs of patients.
This week’s Research Roundup highlights the development and validation of a prostate cancer genomic signature that predicts early androgen deprivation therapy (ADT) treatment response following radical prostatectomy.
Melanoma, the skin cancer often associated with sun exposure, is on the rise and has no reliable cure. Mayo Clinic is at the forefront of these efforts. The Center for Individualized Medicine is unraveling the complex behavior of melanoma at the molecular level—to allow for treatment that better targets an individual’s disease.
This week’s Research Roundup highlights potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations.